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Edited by Ulf-Ingo Fl€uggeAbstract Jasmonic acid (JA) plays a crucial role in plant
fertility and defense responses. It exerts an inhibitory eﬀect on
plant growth when applied exogenously. This eﬀect seems to be
somehow related to a negative regulation of cell cycle progres-
sion in the meristematic tissues. In this report, we focus on the
molecular events that occur during JA-induced G2 arrest. We
demonstrate that JA prevents the accumulation of B-type cyclin-
dependent kinases and the expression of cyclin B1;1, which are
both essential for the initiation of mitosis. This feature suggests
the existence of an early G2 checkpoint that is aﬀected by JA.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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G2/M transition1. Introduction
Cyclin-dependent kinases (CDKs) play a central regulatory
role during cell division in all eukaryotic cells [1]. Their activity
is strictly controlled at the time of the G1/S and G2/M tran-
sitions of the cell cycle by means of phosphorylation and in-
teractions with regulatory subunits [2]. One class of those
subunits, called cyclins, determines the substrate speciﬁcity and
subcellular localization of the kinase [3]. Cyclins are expressed
at speciﬁc stages of the cell cycle and are rapidly degraded.
There are three major types of cyclins in plants. D-type cyclins
are expressed at the initial stage of the cell division, followed
by A-type cyclins, which are thought to control DNA-repli-
cation and related events. Finally, the B-type cyclins accu-
mulate prior to the onset of mitosis [4]. In a previous report [5],
we demonstrated that jasmonic acid (JA) prevents the G1/S
and G2/M transitions in synchronized tobacco BY-2 cells. We
noted an interesting discrepancy: when JA was applied during
S-phase, it prevented cells from entering mitosis without di-
rectly aﬀecting their DNA synthesis. However, when applied
during G2 phase, its eﬀect on mitosis was negligible. There is
approximately a 3-h interval between the S-phase and mitosis,
during which exogenously added JA rapidly accumulates in the* Corresponding author. Fax: +32-3820-2271.
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Abbreviations: JA, jasmonic acid; CDK, cyclin-dependent kinase;
DAPI, 40,60-diamidino-2-phenylindole hydrochloride; GUS, b-glucu-
ronidase; MU, 4-methyl umbelliferone
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Yet, none of those compounds seem to have any eﬀect on cell
cycle progression between the S-phase and mitosis [6].
With the experiments described in this study, we examined
the molecular mechanisms responsible for the anti-mitotic
properties of JA. In order to pinpoint possible targets of JA
action during G2, the expression of the mitotic markers cyclin
B1;1 and B-type CDK upon JA treatment was studied. The
resulting data provide evidence that JA induces G2 arrest in
quite a unique manner. It decreases the histone H1 kinase
activity of the CDK complexes and prevents the accumulation
of cyclin B1;1 and CDK-B during G2. These features exhibit
the characteristics of an early G2 checkpoint.2. Materials and methods
2.1. Chemicals and equipment
All chemicals and basic materials were obtained from Sigma (Bor-
nem, Belgium), unless mentioned otherwise.
2.2. Cell culture and synchronization
The BY-2 cells were maintained as described by Nagata et al. [7].
The culture was kept at 27 C in constant darkness and rotating at 130
rpm. The synchronization protocol was based on the method of
Nagata et al. [7]. The stationary culture was transferred in a propor-
tion of 14:100 to the fresh medium and supplied with 5 mgL1 aphi-
dicolin (ICN Biomedicals, Asse, Belgium). After 24 h of incubation,
the cells were released by extensive washing with fresh medium and
were subjected to the treatments as indicated in the text. The
pCycB1;1::GUS [pCDG] construct (a gift from P. Doerner) was in-
troduced into disarmed Agrobacterium tumefaciens C58pMP90 by
electroporation and the resulting Agrobacterium strain was used to
transform the BY-2 cells according to [8].
2.3. Protein extraction and histone H1 kinase assays
Kinase activity was measured according to [9] with modiﬁcations as
described [5]. Hundred lg of protein was incubated at 4 C for 2 h with
p13Suc1agarose beads (Oncogene, San Diego) or anti-CDK-B antibody
[10]. The latter was afterwards precipitated using protein A or G
agarose (Amersham, Freiburg, Germany). The samples were analyzed
by SDS–PAGE in 17.5% (w/v) acrylamide gel. The incorporated ra-
dioactivity of histone H1 was visualized and quantiﬁed on a Phos-
phorImager (Molecular Dynamics, Sunnyvale, CA). Western blots
were performed according to [11].
2.4. b-Glucuronidase assay and mitotic index determination
Protein extracts were prepared by grinding cells to a ﬁne powder in
liquid N2 with mortar and pestle. Frozen powder was suspended in a
50 mM sodium phosphate buﬀer of pH 7.0, supplied with 10 mM b-
mercaptoethanol, 10 mM EDTA and 0.1% Triton X-100. The samples
were cleared by centrifugation at 4 C and 13 000 rpm for 15 min.
b-Glucuronidase (GUS) activity was measured according to [12].
Reaction progress was monitored with a SpectraMAX (Molecularation of European Biochemical Societies.
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355 nm, emission 450 nm). Prior to the mitotic index measurements,
the cells were ﬁxed in ethanol:acetic acid 3:1 [v/v], stained with 40,60-
diamidino-2-phenylindole hydrochloride (DAPI) and examined under
a ﬂuorescence microscope (Nikon Instruments, Analis SA, Ghent,
Belgium).3. Results
3.1. Jasmonic acid targets S-phase
In order to determine which part of the cell cycle is speciﬁ-
cally targeted by JA, we tested whether the removal of JA after
1 or 2 h of treatment during S-phase could restore mitotic
activity (Fig. 1). A synchronization experiment was performed,
during which the aphidicolin-released culture was divided into
two pools. One was left untreated, while the other one received
100 lM JA immediately after aphidicolin release and was
subsequently divided into three sub-cultures. The untreated
control sub-culture reached a mitotic peak of 39% 5 h after
aphidicolin release. The continuous presence of 100 lM JA
caused a delay and reduction of the mitotic peak to 21% after 7
h. Removal of JA after 2 h or even after 1 h did not reverse the
JA-induced decrease or delay of the mitotic peak. In a separate
experiment, we demonstrated that washing in itself had no
eﬀect on the mitotic index of the synchronized culture, and
that the washing procedure removed more than 90% of the JA
taken up by the cells (data not shown). Those facts and our
earlier observations [5] suggest that JA-induced arrest in G2 is
imprinted during the ﬁrst hour of the experiment, when cells
are engaged in S-phase, which under our laboratory condi-
tions, is completed within 2 h after aphidicolin release of to-
bacco BY-2 cells [5].
3.2. Jasmonic acid negatively regulates CDK activity
Taking this into consideration, we examined the eﬀect of JA
on the expression of the A- and B-type CDK complexes and
their histone H1 kinase activity during S, G2 and mitosis in
synchronized tobacco BY-2 cells (Fig. 2). At 200 lM concen-
tration, JA completely abolished mitosis. The protein content
of both types of CDK was examined by Western blot
(Fig. 2A). The CDK-A level remained constant throughout theFig. 1. The duration of JA treatment and the mitotic activity of BY-2
cells, synchronized using aphidicolin. Hundred lM JA was applied
immediately after the release and subsequently removed by washing
after 1 or 2 h of incubation. The mitotic index was compared to the
untreated control and the continuously treated culture.experiment and was unaﬀected by the JA-treatment. In ac-
cordance with previously reported data [10], the CDK-B level
gradually increased, reaching its maximum level at 6 h after
aphidicolin release (1 h before the peak of the mitotic index),
and then slightly decreased. JA treatment strongly reduced the
overall protein level of this kinase, although a similar accu-
mulation proﬁle with a peak at 6 h was still clearly visible. The
total histone H1 kinase activity of both CDK complexes was
measured upon aﬃnity puriﬁcation with p13Suc1 beads (Fig. 2).
The kinase activity remained unaltered during the ﬁrst two
hours following JA treatment, after which we observed an
increased activity in the untreated control and a reduced ac-
tivity in the JA-treated cells. Upon immunoprecipitation, using
a speciﬁc anti-CDK-B antibody, the kinase activity of the B-
type CDKs was measured after 6, 7 and 8 h, corresponding to
the highest accumulation of the CDK-B protein (Fig. 2). In the
untreated control cells, the activity was the highest after 7 h, at
which time the synchronized culture displayed the peak of
mitotic activity. Concomitant with the decrease of the B-type
kinase protein level, a treatment with 200 lM JA reduced the
B-type CDK activity by approximately 60%.
3.3. CyclinB1;1 accumulation is inhibited by JA
In order to examine the accumulation proﬁle of cyclin B1;1,
we used transgenic BY-2 cells harboring a CYCB1;1 reporter
line in which the CYCB1;1 promoter and N-terminal de-
struction box are fused in-frame with GUS [13]. During the cell
cycle progression of the synchronized BY-2 control culture, the
GUS activity correlated well with the mitotic index (Fig. 3). It
remained low until 5 h after aphidicolin release. Then, it in-
creased approximately 20-fold at 7 h and rapidly decreased
afterwards. In cultures treated with JA, the GUS activity was
also in correlation with the mitotic index. Treatment with 150
lM JA completely abolished mitotic activity and the GUS
activity remained low, not exceeding the background level.
Compared to the control cells, in which we observed a mitotic
peak of 32% after 7 h, the mitotic peak in the cultures treated
with 75 lM JA was delayed with about 4 h, and decreased to
17%. The peak of GUS activity in the 75 lM JA-treated cul-
ture was also delayed for about 4 h, only to reach a maximum
of merely 43% of the highest GUS activity detected in the
control cells.
3.4. Comparison of the eﬀects of roscovitine and JA on mitotic
index and cyclinB1;1 accumulation
Because the decrease of CDK activity preceded the reduced
accumulation of cyclin B1;1 upon JA treatment, we wanted to
investigate whether these two phenomena are directly linked.
Therefore, we applied roscovitine to mimic the inhibitory eﬀect
of JA on CDK activity. Analogous to the application of 100
lM JA during the S-phase, 50 lM of roscovitine caused a
delay of about 4 h and a strong reduction of mitotic activity
when applied 3 h after aphidicolin release (Fig. 1 and 3). The
accumulation of CYCB1;1-GUS was delayed by the roscovi-
tine treatment, suggesting that there is a certain relation be-
tween CDK activity and the induction of cyclin B1;1
expression. However, in contrast with the observed decrease in
JA-treated cells, roscovitine caused CYCB1;1-GUS to accu-
mulate, reaching values about two times higher than those
observed in the control cells (Fig. 3). This further indicates that
JA reduces the expression of cyclin B1;1 independently of the
negative regulation of CDK activity.
Fig. 2. Protein level and activity of CDKs after JA treatment. The cells were synchronized using aphidicolin and subjected to treatment with 200 lM
JA, or kept untreated as a control. The cell cycle progression was analyzed by means of the mitotic index and both cultures were sampled at 1 h
intervals. (A) Left: mitotic index aligned with histone H1 kinase activity in treated and untreated cultures; right: protein levels of CDK-A and CDK-
B kinases, visualized by Western blot. (B) Quantiﬁed data from kinase assays shown in (A), data averaged from two independent measure-
ments S.D.
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In synchronized tobacco BY-2 cells, the activity of CDKs
gradually increases during cells cycle progression from S-phase
to mitosis. However, in JA-treated cells CDK activity started
to decrease signiﬁcantly 2 h after aphidicolin release coinciding
with the end of the S-phase. This fact was consistent with the
observation that DNA synthesis, which requires CDK activity,
progressed undisturbed in the JA-treated cells [5]. Since the
bulk of JA was taken up very rapidly [6], we can conclude that
the time lapse between the JA feeding, obligatory at the be-
ginning of S, and the decrease of CDK activity were not re-
lated to the rate of JA uptake. Furthermore, the removal of JA
in late S could not recover mitosis, suggesting that JA acts
during early S and causes a subsequent decrease in CDK ac-
tivity in G2. The short-term regulation of CDK-A activity isnot dependent on protein turnover, as A-type CDK kinases
have a long half-life [14] and are expressed in all plant cells that
show competence for cell division, e.g. [15]. Their activities
depend largely on several other factors: the phosphorylation of
conserved residues, the presence or absence of inhibitor pro-
teins from the KRP family, and the availability of their acti-
vating cyclin partners, which have a cell cycle-dependent
expression pattern and are degraded in a strictly regulated
fashion [2]. The CYCB1;1 protein is expressed starting from
late G2 and the protein is rapidly degraded during the ana-
phase [16], making it a suitable marker for G2/M transition.
JA treatment inhibited the accumulation of the chimeric
CYCB1;1-GUS protein in a concentration-dependent manner.
The inhibition was not due to increased cyclin degradation,
because in an alternative system, where GUS expression was
controlled by a CYCB1;1 promoter and the protein stability
Fig. 3. The eﬀect of JA and roscovitine on the expression of CYCB1;1 in synchronized tobacco BY-2 cells, transformed with a pCYCB1;1::GUS
construct. (Left) JA was applied immediately after aphidicolin release; (right) cells treated with 50 lM roscovitine, 3 h after aphidicolin release. The
upper graphs represent mitotic index, the lower graphs represent GUS activity, averaged from three measurementsS.D.
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activation of expression was also prevented by JA (data not
shown). The CDK-B kinase was another mitotic marker we
studied. The observed reduction of the CDK-B protein level
correlated with the decrease of its activity. Unlike the
CYCB1;1-GUS expression, it did not decline to background
levels, even after a treatment with 200 lM JA, which com-
pletely inhibited mitosis. The fact that the CDK-B activity was
not completely abolished might seem somewhat surprising,
because the accumulation of mitotic CYCB1;1 protein was
completely blocked at this level of JA concentration. One
would expect a complete loss of CDK-B activity as well, but it
has been recently suggested that cyclin B2 [17], rather than
cyclin B1, forms a complex with CDK-B, and its expression
might be diﬀerentially regulated by JA. It seems signiﬁcant,
however, that during the JA-induced cell cycle arrest, both
CYCB1;1 and CDK-B accumulation were prevented. Al-
though both proteins accumulate at mitotic entry, their ex-
pression is probably regulated by diﬀerent mechanisms; the
MSA elements that mediate G2/M-speciﬁc transcription are
only present in a CYCB1;1 promoter and not in CDK-B
[18,19]. Therefore, the levels of those two proteins are proba-
bly indirectly inﬂuenced by JA.
We tried to ﬁnd out whether a decrease in CDK activity,
which was observed upon JA treatment, could negatively
regulate the expression of CYCB1;1. However, in contrast toJA, a strong accumulation of GUS activity was observed after
treatment with roscovitine, a potent inhibitor of the CDK
activity. This is consistent with the fact that CDK-dependent
phosphorylation targets CYCB1;1 for proteasome degradation
[16]. Consequently, when the kinase is inhibited by roscovitine,
the fusion protein that contains a cyclin destruction box ac-
cumulates. A very similar case has been observed in human
ﬁbroblast cells, where UV-C-induced DNA damage, which
negatively regulates CDK activity, leads to cell cycle arrest and
a decrease in CYCB1 mRNA levels, yet also causes the accu-
mulation of CYCB1 protein [20]. Another possibility is that
roscovitine arrests cells in the phase where one of the yet un-
identiﬁed factors required for the destruction of cyclin B1;1-
GUS protein is not expressed. Taking all the data together, it
seems that JA causes an arrest in early G2, before the induc-
tion of expression of CYCB1;1 and CDK-B takes place. This
was further corroborated by the fact that neither zeatin, which
is thought to be a positive regulator of G2/M transition at the
CDK level [21], nor caﬀeine, which overrides ATM-dependent
G2 arrest [22], could reverse the eﬀect of JA (Swiatek, un-
published data). It seems very likely that JA-treated cells arrest
somewhere before the G2/M checkpoints that are targeted by
these two agents.Acknowledgements: The authors thank Prof. Herman Slegers and his
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